$DNTH
Dianthus Therapeutics, Inc. /DE/

2023 Q4 Form 10-Q Financial Statement

#000095017023062070 Filed on November 09, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3 2022 Q4
Revenue $457.0K $924.0K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.632M $8.720M $5.942M
YoY Change -22.05% 44.08% -15.43%
% of Gross Profit
Research & Development $8.781M $7.960M $15.79M
YoY Change -44.39% -28.93% 20.41%
% of Gross Profit
Depreciation & Amortization $17.00K $19.00K $466.0K
YoY Change -96.35% -95.97% -12.9%
% of Gross Profit
Operating Expenses $13.41M $16.68M $21.73M
YoY Change -38.28% -3.3% 7.9%
Operating Profit -$15.76M
YoY Change -8.66%
Interest Expense $2.412M $1.010M $1.554M
YoY Change 55.21% -15.13% 83.25%
% of Operating Profit
Other Income/Expense, Net -$19.00K $996.0K
YoY Change 111.91%
Pretax Income -$10.56M -$14.76M -$20.18M
YoY Change -47.65% -8.11% 4.59%
Income Tax
% Of Pretax Income
Net Earnings -$10.56M -$14.76M -$20.18M
YoY Change -47.65% -8.09% 4.59%
Net Earnings / Revenue -2311.38% -1597.73%
Basic Earnings Per Share -$3.78
Diluted Earnings Per Share -$0.71 -$3.78 -$0.33
COMMON SHARES
Basic Shares Outstanding 14.82M 60.66M 60.56M
Diluted Shares Outstanding 3.907M

Balance Sheet

Concept 2023 Q4 2023 Q3 2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $173.7M $189.9M $112.0M
YoY Change 55.05% 48.03% -36.67%
Cash & Equivalents $132.3M $157.3M $57.63M
Short-Term Investments $41.39M $32.60M $54.42M
Other Short-Term Assets $3.255M $800.0K $3.561M
YoY Change -8.59% -79.02% -5.47%
Inventory
Prepaid Expenses
Receivables $294.0K $232.0K $4.700M
Other Receivables $0.00 $0.00
Total Short-Term Assets $177.5M $191.5M $115.6M
YoY Change 53.5% 44.93% -36.02%
LONG-TERM ASSETS
Property, Plant & Equipment $185.0K $195.0K $6.095M
YoY Change -96.96% -96.91% -18.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.154M $100.0K $1.780M
YoY Change -35.17% -94.38% 0.0%
Total Long-Term Assets $1.954M $1.009M $31.04M
YoY Change -93.71% -96.85% 235.93%
TOTAL ASSETS
Total Short-Term Assets $177.5M $191.5M $115.6M
Total Long-Term Assets $1.954M $1.009M $31.04M
Total Assets $179.4M $192.5M $146.6M
YoY Change 22.34% 17.27% -22.79%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $2.610M $1.369M $2.454M
YoY Change 6.36% -46.9% -19.28%
Accrued Expenses $6.504M $11.20M $8.271M
YoY Change -21.36% 66.57% 5.73%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $9.631M $13.08M $14.55M
YoY Change -33.8% 1.22% 33.93%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $904.0K $1.000M $26.14M
YoY Change -96.54% -96.32% 308.47%
Total Long-Term Liabilities $904.0K $1.000M $26.14M
YoY Change -96.54% -96.32% 308.47%
TOTAL LIABILITIES
Total Short-Term Liabilities $9.631M $13.08M $14.55M
Total Long-Term Liabilities $904.0K $1.000M $26.14M
Total Liabilities $10.54M $14.08M $40.69M
YoY Change -74.11% -64.88% 135.7%
SHAREHOLDERS EQUITY
Retained Earnings -$89.40M -$78.90M -$402.0M
YoY Change -77.76% -79.34% 23.48%
Common Stock $258.2M $257.2M $508.2M
YoY Change -49.18% -49.2% 1.99%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $168.9M $178.4M $106.0M
YoY Change
Total Liabilities & Shareholders Equity $179.4M $192.5M $146.6M
YoY Change 22.34% 17.27% -22.79%

Cashflow Statement

Concept 2023 Q4 2023 Q3 2022 Q4
OPERATING ACTIVITIES
Net Income -$10.56M -$14.76M -$20.18M
YoY Change -47.65% -8.09% 4.59%
Depreciation, Depletion And Amortization $17.00K $19.00K $466.0K
YoY Change -96.35% -95.97% -12.9%
Cash From Operating Activities -$11.85M $17.13M -$16.69M
YoY Change -28.98% -224.06% 6.36%
INVESTING ACTIVITIES
Capital Expenditures $10.00K -$150.0K $0.00
YoY Change -5.06% -100.0%
Acquisitions
YoY Change
Other Investing Activities -$8.227M -$17.03M $15.22M
YoY Change -154.05% -210.59% -247.65%
Cash From Investing Activities -$8.237M -$16.88M $15.22M
YoY Change -154.12% -210.75% -247.44%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -4.866M 138.4M 66.00K
YoY Change -7472.73% 4910.5% -46.77%
NET CHANGE
Cash From Operating Activities -11.85M 17.13M -16.69M
Cash From Investing Activities -8.237M -16.88M 15.22M
Cash From Financing Activities -4.866M 138.4M 66.00K
Net Change In Cash -24.95M 138.7M -1.402M
YoY Change 1679.89% 3205.29% -94.58%
FREE CASH FLOW
Cash From Operating Activities -$11.85M $17.13M -$16.69M
Capital Expenditures $10.00K -$150.0K $0.00
Free Cash Flow -$11.86M $17.28M -$16.69M
YoY Change -28.92% -226.59% 6.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14748000
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Entity Central Index Key
EntityCentralIndexKey
0001690585
dei Amendment Flag
AmendmentFlag
false
CY2022 dnth Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel2
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2023-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38541
dei Entity Registrant Name
EntityRegistrantName
Dianthus Therapeutics, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
81-0724163
dei Entity Address Address Line1
EntityAddressAddressLine1
7 Times Square, 43rd Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
New York
dei Entity Address State Or Province
EntityAddressStateOrProvince
NY
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
10036
dei City Area Code
CityAreaCode
929
dei Local Phone Number
LocalPhoneNumber
999-4055
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
DNTH
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2023Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
14817762
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
157282000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
15365000
CY2023Q3 us-gaap Short Term Investments
ShortTermInvestments
32588000
CY2022Q4 us-gaap Short Term Investments
ShortTermInvestments
60125000
CY2023Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
232000
CY2022Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
4700000
CY2023Q3 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
519000
CY2022Q4 us-gaap Unbilled Receivables Current
UnbilledReceivablesCurrent
938000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
832000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
905000
CY2023Q3 us-gaap Assets Current
AssetsCurrent
191453000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
82033000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
195000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
142000
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
698000
CY2022Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
814000
CY2023Q3 dnth Other Assets And Restricted Cash
OtherAssetsAndRestrictedCash
116000
CY2022Q4 dnth Other Assets And Restricted Cash
OtherAssetsAndRestrictedCash
121000
CY2023Q3 us-gaap Assets
Assets
192462000
CY2022Q4 us-gaap Assets
Assets
83110000
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
1369000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1167000
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
11197000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
6608000
CY2023Q3 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
100000
CY2022Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
100000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
413000
CY2022Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
350000
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
13079000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
8225000
CY2023Q3 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
745000
CY2022Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
791000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
257000
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
438000
CY2023Q3 us-gaap Liabilities
Liabilities
14081000
CY2022Q4 us-gaap Liabilities
Liabilities
9454000
CY2023Q3 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Temporary Equity Par Or Stated Value Per Share
TemporaryEquityParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
0
CY2022Q4 us-gaap Temporary Equity Shares Authorized
TemporaryEquitySharesAuthorized
33336283
CY2023Q3 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
0
CY2023Q3 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
0
CY2022Q4 us-gaap Temporary Equity Shares Issued
TemporaryEquitySharesIssued
33336282
CY2022Q4 us-gaap Temporary Equity Shares Outstanding
TemporaryEquitySharesOutstanding
33336282
CY2023Q3 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
0
CY2022Q4 us-gaap Temporary Equity Liquidation Preference
TemporaryEquityLiquidationPreference
121500
CY2023Q3 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
0
CY2022Q4 us-gaap Temporary Equity Carrying Amount Attributable To Parent
TemporaryEquityCarryingAmountAttributableToParent
118024000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
0
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
40000000
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
14817762
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
14817762
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
875279
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
875279
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
15000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
0
CY2023Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
257230000
CY2022Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
1661000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78860000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-45868000
CY2023Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-4000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-161000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
178381000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-44368000
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
192462000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83110000
CY2023Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
924000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1173000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2369000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5242000
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7960000
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
7218000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
24060000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
19548000
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8723000
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2209000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13527000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4706000
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
16683000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
9427000
us-gaap Operating Expenses
OperatingExpenses
37587000
us-gaap Operating Expenses
OperatingExpenses
24254000
CY2023Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-15759000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-8254000
us-gaap Operating Income Loss
OperatingIncomeLoss
-35218000
us-gaap Operating Income Loss
OperatingIncomeLoss
-19012000
CY2023Q3 us-gaap Interest Income Other
InterestIncomeOther
1027000
CY2022Q3 us-gaap Interest Income Other
InterestIncomeOther
416000
us-gaap Interest Income Other
InterestIncomeOther
2320000
us-gaap Interest Income Other
InterestIncomeOther
505000
CY2023Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-16000
CY2022Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
56000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-53000
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
156000
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-15000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-2000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-41000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-9000
CY2023Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
996000
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
470000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2226000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
652000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14763000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7784000
us-gaap Net Income Loss
NetIncomeLoss
-32992000
us-gaap Net Income Loss
NetIncomeLoss
-18360000
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.78
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.78
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.9
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.9
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-17.4
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-17.4
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-21
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3906886
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3906886
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
874327
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
874327
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1896605
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1896605
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
874138
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
874138
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14763000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7784000
us-gaap Net Income Loss
NetIncomeLoss
-32992000
us-gaap Net Income Loss
NetIncomeLoss
-18360000
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
15000
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-150000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
157000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-150000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
15000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-150000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
157000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-150000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2546000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7934000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-32835000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-18510000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-44368000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
533000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-7089000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
104000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-50820000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
462000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-11140000
CY2023Q2 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
38000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
-61460000
CY2023Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
5000
CY2023Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
118024000
CY2023Q3 dnth Stock Issuance Cost
StockIssuanceCost
4250000
CY2023Q3 dnth Issuance Of Common Stock And Pre Funded Warrants In The Pre Closing Financing Net Of Issuance Costs
IssuanceOfCommonStockAndPreFundedWarrantsInThePreClosingFinancingNetOfIssuanceCosts
67750000
CY2023Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
71595000
CY2023Q3 dnth Reverse Recapitalization Transaction Costs
ReverseRecapitalizationTransactionCosts
3964000
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1179000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14763000
CY2023Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
15000
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
178381000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-17249000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
65000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-4881000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-22065000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
279000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-5695000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-27481000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
661000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7784000
CY2022Q3 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-150000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
-34754000
us-gaap Profit Loss
ProfitLoss
-32992000
us-gaap Profit Loss
ProfitLoss
-18360000
us-gaap Depreciation
Depreciation
47000
us-gaap Depreciation
Depreciation
19000
us-gaap Share Based Compensation
ShareBasedCompensation
2174000
us-gaap Share Based Compensation
ShareBasedCompensation
1005000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
896000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
204000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
205000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
79000
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-4468000
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
1083000
dnth Unbilled Receivable From Related Party
UnbilledReceivableFromRelatedParty
419000
dnth Unbilled Receivable From Related Party
UnbilledReceivableFromRelatedParty
-1927000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
862000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-10000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
49000
dnth Accounts Payable Accrued Expenses And Lease Liabilities
AccountsPayableAccruedExpensesAndLeaseLiabilities
-942000
dnth Accounts Payable Accrued Expenses And Lease Liabilities
AccountsPayableAccruedExpensesAndLeaseLiabilities
249000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-46000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
914000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25007000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20219000
us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
100000
us-gaap Payments For Capital Improvements
PaymentsForCapitalImprovements
110000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
31195000
us-gaap Payments To Acquire Short Term Investments
PaymentsToAcquireShortTermInvestments
47044000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
59785000
us-gaap Proceeds From Maturities Prepayments And Calls Of Shortterm Investments
ProceedsFromMaturitiesPrepaymentsAndCallsOfShorttermInvestments
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
28490000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-47154000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
5000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
dnth Proceeds From The Pre Closing Financing
ProceedsFromThePreClosingFinancing
72000000
dnth Proceeds From The Pre Closing Financing
ProceedsFromThePreClosingFinancing
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
50000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
dnth Cash Acquired In Connection With The Reverse Recapitalization
CashAcquiredInConnectionWithTheReverseRecapitalization
69738000
dnth Cash Acquired In Connection With The Reverse Recapitalization
CashAcquiredInConnectionWithTheReverseRecapitalization
0
dnth Payment Of Reverse Recapitalization Transaction Costs
PaymentOfReverseRecapitalizationTransactionCosts
3254000
dnth Payment Of Reverse Recapitalization Transaction Costs
PaymentOfReverseRecapitalizationTransactionCosts
0
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
377000
us-gaap Proceeds From Notes Payable
ProceedsFromNotesPayable
0
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
377000
us-gaap Repayments Of Notes Payable
RepaymentsOfNotesPayable
0
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
100000000
us-gaap Payments For Repurchase Of Convertible Preferred Stock
PaymentsForRepurchaseOfConvertiblePreferredStock
0
us-gaap Payments For Repurchase Of Convertible Preferred Stock
PaymentsForRepurchaseOfConvertiblePreferredStock
3324000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
138439000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
96676000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
141922000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
29303000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15425000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7638000
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
157347000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36941000
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
157282000
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36881000
CY2023Q3 us-gaap Restricted Cash
RestrictedCash
65000
CY2022Q3 us-gaap Restricted Cash
RestrictedCash
60000
CY2023Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
157347000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
36941000
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Interest Paid Net
InterestPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
0
dnth Issuance Costs In Connection With Pre Closing Financing Included In Accrued Expenses
IssuanceCostsInConnectionWithPreClosingFinancingIncludedInAccruedExpenses
4200000
dnth Issuance Costs In Connection With Pre Closing Financing Included In Accrued Expenses
IssuanceCostsInConnectionWithPreClosingFinancingIncludedInAccruedExpenses
0
dnth Transaction Costs Related To Reverse Recapitalization Included In Accounts Payable And Accrued Expenses
TransactionCostsRelatedToReverseRecapitalizationIncludedInAccountsPayableAndAccruedExpenses
710000
dnth Transaction Costs Related To Reverse Recapitalization Included In Accounts Payable And Accrued Expenses
TransactionCostsRelatedToReverseRecapitalizationIncludedInAccountsPayableAndAccruedExpenses
0
dnth Conversion Of Convertible Preferred Stock Into Common Stock
ConversionOfConvertiblePreferredStockIntoCommonStock
118024000
dnth Conversion Of Convertible Preferred Stock Into Common Stock
ConversionOfConvertiblePreferredStockIntoCommonStock
0
dnth Additions To Right Of Use Lease Assets From New Operating Lease Liabilities
AdditionsToRightOfUseLeaseAssetsFromNewOperatingLeaseLiabilities
89000
dnth Additions To Right Of Use Lease Assets From New Operating Lease Liabilities
AdditionsToRightOfUseLeaseAssetsFromNewOperatingLeaseLiabilities
931000
CY2023Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
Immediately prior to the effective time of the Reverse Merger, the Company effected a 1-for-16 reverse stock split of its common stock (the “Reverse Stock Split”). Unless noted otherwise, all references herein to share and per share amounts reflect the Reverse Stock Split.
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11021248
CY2023Q3 dnth Split Adjusted Exchange Ratio Of Reverse Merger
SplitAdjustedExchangeRatioOfReverseMerger
0.2181
CY2023Q3 dnth Split Adjusted Exchange Ratio Of Reverse Merger
SplitAdjustedExchangeRatioOfReverseMerger
0.2181
CY2023Q3 dnth Shares Of Common Stock Issued In Pre Closing Financing
SharesOfCommonStockIssuedInPreClosingFinancing
2873988
CY2023Q3 dnth Shares Pre Funded Warrants To Purchase
SharesPreFundedWarrantsToPurchase
210320
CY2023Q3 dnth Pre Funded Warrants Exercisable
PreFundedWarrantsExercisable
210320
CY2023Q3 dnth Common Stock Price Per Share
CommonStockPricePerShare
23.34
CY2023Q3 dnth Prefunded Warrants Price Per Share
PrefundedWarrantsPricePerShare
23.34
CY2023Q3 dnth Proceeds From Pre Closing Financing
ProceedsFromPreClosingFinancing
72000000
us-gaap Net Income Loss
NetIncomeLoss
-33000000
us-gaap Net Income Loss
NetIncomeLoss
-18400000
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78900000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-78900000
us-gaap Use Of Estimates
UseOfEstimates
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Use of Estimates</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results may differ materially from those estimates.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates including the following: expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes, and management must select an amount that falls within that range of reasonable estimates. Significant estimates are used in the following areas, among others: the recognition of research and development expense, stock-based compensation expense and revenue recognition.</span></p>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Concentration of Credit Risk</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash, cash equivalents and short-term investments. The Company regularly maintains deposits in accredited financial institutions in excess of federally insured limits. The Company invests its excess cash primarily in money market funds, U.S. treasury securities and U.S. government agency securities in accordance with the Company’s investment policy. The Company’s investment policy defines allowable investments and establishes guidelines relating to credit quality, diversification, and maturities of its investments to preserve</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">principal and maintain liquidity. The Company has not experienced any realized losses related to its cash, cash equivalents and short-term investments and management believes the Company is not exposed to significant risks of losses.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023 and December 31, 2022</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">, the Company held cash deposits at Silicon Valley Bank (“SVB”) in excess of government insured limits. On March 10, 2023, SVB was closed by the California Department of Financial Protection and Innovation, and the Federal Deposit Insurance Corporation was appointed as receiver. No losses were incurred by the Company on deposits that were held at SVB. Management believes that the Company is not currently exposed to significant credit risk as the vast majority of the Company’s deposits were either owned directly by the Company and held in custody at a third-party financial institution or, subsequent to March 10, 2023, have been transferred to a third-party financial institution. The Company does not currently have any other significant relationships with SVB.</span></p>
CY2023Q3 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Writeoff
DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
0
us-gaap Debt Securities Available For Sale Allowance For Credit Loss Writeoff
DebtSecuritiesAvailableForSaleAllowanceForCreditLossWriteoff
0
CY2022Q4 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2023Q3 us-gaap Allowance For Doubtful Accounts Receivable
AllowanceForDoubtfulAccountsReceivable
0
CY2023Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
32586000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
4000
CY2023Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
2000
CY2023Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
0
us-gaap Revenue Recognition Services Licensing Fees
RevenueRecognitionServicesLicensingFees
<p style="text-indent:0;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">License Revenue – Related Party</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">To date, the Company’s only revenue has been attributable to an upfront payment and cost reimbursements under the Company’s license agreement with Zenas. The Company has not generated any revenue from product sales and does not expect to generate any revenue from product sales for the foreseeable future.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company recognizes revenue pursuant to ASC 606, </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;font-style:italic;min-width:fit-content;">Revenue from Contracts with Customers</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> (“ASC 606”). ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards. Under ASC 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when the performance obligation is satisfied.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company evaluates the performance obligations promised in a contract that are based on goods and services that will be transferred to the customer and determine whether those obligations are both (i) capable of being distinct and (ii) distinct in the context of the contract. To the extent a contract includes multiple promised goods and services, the Company applies judgment to determine whether promised goods and services are both capable of being distinct and are distinct in the context of the contract. If these criteria are not met, the promised goods and services are accounted for as a combined performance obligation. Arrangements that include rights to additional goods or services that are exercisable at a customer’s discretion are generally considered options. The Company assesses if these options provide a material right to the customer and if so, they are considered performance obligations.</span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company estimates the transaction price based on the amount expected to be received for transferring the promised goods or services in the contract. The consideration may include fixed consideration or variable consideration. At the inception of each arrangement that includes variable consideration, the Company evaluates the amount of potential transaction price and the likelihood that the transaction price will be received. Variable consideration is included in the transaction price if, in management’s judgment, it is probable that a significant future reversal of cumulative revenue under the contract will not occur. Any estimates, including the effect of the constraint on variable consideration, are evaluated at each reporting period for any changes. The Company then allocates the transaction price to each performance obligation and recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) control is transferred to the customer and the performance obligation is satisfied.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Amounts received prior to satisfying the revenue recognition criteria are recorded as deferred revenue in the Company’s balance sheets. If the related performance obligation is expected to be satisfied within the next twelve months this will be classified in current liabilities.</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Additional information and disclosures required under ASC 606 are included in Note 13.</span></p>
CY2023Q3 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
69738000
CY2023Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
2473000
CY2023Q3 dnth Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Accrued Liabilities
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedAccruedLiabilities
616000
CY2023Q3 us-gaap Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net
BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet
71595000
CY2023Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
32588000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
60286000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
3000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
164000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
60125000
CY2023Q3 dnth Prepaid Materials Supplies And Research And Development Services
PrepaidMaterialsSuppliesAndResearchAndDevelopmentServices
337000
CY2022Q4 dnth Prepaid Materials Supplies And Research And Development Services
PrepaidMaterialsSuppliesAndResearchAndDevelopmentServices
820000
CY2023Q3 dnth Prepaid Subscriptions Software And Other Administrative Services
PrepaidSubscriptionsSoftwareAndOtherAdministrativeServices
475000
CY2022Q4 dnth Prepaid Subscriptions Software And Other Administrative Services
PrepaidSubscriptionsSoftwareAndOtherAdministrativeServices
53000
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
20000
CY2022Q4 us-gaap Prepaid Insurance
PrepaidInsurance
32000
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
832000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
905000
CY2023Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
272000
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
172000
CY2023Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
77000
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
30000
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
195000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
142000
CY2023Q3 us-gaap Depreciation
Depreciation
19000
us-gaap Depreciation
Depreciation
47000
CY2022Q3 us-gaap Depreciation
Depreciation
6000
us-gaap Depreciation
Depreciation
19000
dnth Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel1
0
dnth Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level2
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel2
0
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level3
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
0
CY2022 dnth Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Into Level1
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel1
0
CY2023Q3 dnth Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
1001000
CY2022Q4 dnth Accrued External Research And Development Expenses Current
AccruedExternalResearchAndDevelopmentExpensesCurrent
4329000
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4429000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2084000
CY2023Q3 dnth Accrued Issuance Costs In Connection With Pre Closing Financing
AccruedIssuanceCostsInConnectionWithPreClosingFinancing
4200000
CY2022Q4 dnth Accrued Issuance Costs In Connection With Pre Closing Financing
AccruedIssuanceCostsInConnectionWithPreClosingFinancing
0
CY2023Q3 dnth Accrued Transaction Costs Related To Reverse Recapitalization
AccruedTransactionCostsRelatedToReverseRecapitalization
419000
CY2022Q4 dnth Accrued Transaction Costs Related To Reverse Recapitalization
AccruedTransactionCostsRelatedToReverseRecapitalization
0
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
667000
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
162000
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
481000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
33000
CY2023Q3 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
11197000
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
6608000
us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
The Company leases space under operating leases for administrative offices in New York, New York, and Waltham, Massachusetts and wet laboratory space in Watertown, Massachusetts. The Company also leased office space under operating leases, which had a non-cancelable lease term of less than one year and, therefore, management elected the practical expedient to exclude these short-term leases from right-of-use assets and lease liabilities.
CY2023Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
88000
CY2022Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
66000
us-gaap Operating Lease Cost
OperatingLeaseCost
263000
us-gaap Operating Lease Cost
OperatingLeaseCost
110000
CY2023Q3 us-gaap Variable Lease Cost
VariableLeaseCost
7000
CY2022Q3 us-gaap Variable Lease Cost
VariableLeaseCost
1000
us-gaap Variable Lease Cost
VariableLeaseCost
20000
us-gaap Variable Lease Cost
VariableLeaseCost
4000
CY2023Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
CY2022Q3 us-gaap Short Term Lease Cost
ShortTermLeaseCost
6000
us-gaap Short Term Lease Cost
ShortTermLeaseCost
0
us-gaap Short Term Lease Cost
ShortTermLeaseCost
34000
CY2023Q3 us-gaap Lease Cost
LeaseCost
95000
CY2022Q3 us-gaap Lease Cost
LeaseCost
73000
us-gaap Lease Cost
LeaseCost
283000
us-gaap Lease Cost
LeaseCost
148000
CY2023Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2023Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
102000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
417000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
222000
CY2023Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
741000
CY2023Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
71000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
670000
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
413000
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
257000
CY2023Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
670000
CY2023Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P22M
CY2023Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.106
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
11021248
CY2023Q3 dnth Split Adjusted Exchange Ratio Of Reverse Merger
SplitAdjustedExchangeRatioOfReverseMerger
0.2181
us-gaap Common Stock Dividends Per Share Declared
CommonStockDividendsPerShareDeclared
0
dnth Schedule Of Common Stock Shares Reserved For Future Issuance Table Textblock
ScheduleOfCommonStockSharesReservedForFutureIssuanceTableTextblock
<p style="text-indent:4.533%;font-size:10pt;margin-top:12pt;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company had the following shares of Company common stock reserved for future issuance as of </span><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">September 30, 2023 and December 31, 2022:</span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:12pt;font-family:Times New Roman;min-width:fit-content;"> </span></p> <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"> <tr style="visibility:collapse;"> <td style="width:66.96%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.36%;"></td> <td style="width:1%;"></td> <td style="width:1.16%;"></td> <td style="width:1%;"></td> <td style="width:13.36%;"></td> <td style="width:1%;"></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of September 30, 2023</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td colspan="2" style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:9pt;font-family:Times New Roman;min-width:fit-content;">As of December 31, 2022</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;text-align:left;"><p style="text-indent:0;font-size:9pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:center;"><span style="white-space:pre-wrap;font-size:9pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Conversion of convertible preferred stock</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">7,269,183</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuance of common stock upon exercise of stock options</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,772,179</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">1,273,454</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Equity awards available for grant under stock awards</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">767,454</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">414,679</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Shares available for issuance under the Employee Stock Purchase Plan</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">37,078</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">—</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Issuance of common stock upon exercise of warrants</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">214,997</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:0.5pt solid #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">4,677</span></p></td> <td style="background-color:#cff0fc;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:0.5pt solid #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> <tr style="height:10pt;"> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:top;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Total common stock reserved for future issuance</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">2,791,708</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #000000;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:pre-wrap;vertical-align:bottom;border-bottom:2.25pt double #000000;text-align:center;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:right;"><span style="font-size:10pt;font-family:Times New Roman;color:#000000;white-space:pre-wrap;font-weight:normal;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">8,961,993</span></p></td> <td style="background-color:#ffffff;word-break:break-word;white-space:nowrap;vertical-align:bottom;border-bottom:2.25pt double #ffffff03;"><p style="text-indent:0;font-size:10pt;margin-top:0;font-family:Times New Roman;margin-bottom:0;text-align:left;"><span style="font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p></td> </tr> </table>
CY2023Q3 dnth Conversion Of Convertible Preferred Stock
ConversionOfConvertiblePreferredStock
0
CY2022Q4 dnth Conversion Of Convertible Preferred Stock
ConversionOfConvertiblePreferredStock
7269183
CY2023Q3 dnth Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
1772179
CY2022Q4 dnth Issuance Of Common Stock Upon Exercise Of Stock Options
IssuanceOfCommonStockUponExerciseOfStockOptions
1273454
CY2023Q3 dnth Equity Awards Available For Grant Under Stock Awards
EquityAwardsAvailableForGrantUnderStockAwards
767454
CY2022Q4 dnth Equity Awards Available For Grant Under Stock Awards
EquityAwardsAvailableForGrantUnderStockAwards
414679
CY2023Q3 dnth Shares Available For Issuance Under The Employee Stock Purchase Plan
SharesAvailableForIssuanceUnderTheEmployeeStockPurchasePlan
37078
CY2022Q4 dnth Shares Available For Issuance Under The Employee Stock Purchase Plan
SharesAvailableForIssuanceUnderTheEmployeeStockPurchasePlan
0
CY2023Q3 dnth Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
214997
CY2022Q4 dnth Issuance Of Common Stock Upon Exercise Of Warrants
IssuanceOfCommonStockUponExerciseOfWarrants
4677
CY2023Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
2791708
CY2022Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8961993
CY2023Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q3 us-gaap Convertible Preferred Stock Terms Of Conversion
ConvertiblePreferredStockTermsOfConversion
Under the terms of the Merger Agreement, immediately prior to the effective time of the Reverse Merger, each share of Former Dianthus convertible preferred stock was converted into a share of Former Dianthus common stock.
CY2023Q3 us-gaap Convertible Preferred Stock Shares Issued Upon Conversion
ConvertiblePreferredStockSharesIssuedUponConversion
7269183
CY2023Q3 dnth Split Adjusted Exchange Ratio Of Reverse Merger
SplitAdjustedExchangeRatioOfReverseMerger
0.2181
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
529773
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
94.59
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y2M12D
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0
dnth Share Based Compensation Arrangement By Share Based Payment Assumption Of Options In Connection With Reverse Merger
ShareBasedCompensationArrangementByShareBasedPaymentAssumptionOfOptionsInConnectionWithReverseMerger
1273454
dnth Share Based Compensation Arrangements By Share Based Payment Award Options Assumption Of Options In Connection With The Reverse Merger Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumptionOfOptionsInConnectionWithTheReverseMergerWeightedAverageExercisePrice
7.95
dnth Share Based Compensation Arrangement By Share Based Payment Award Options Assumption Of Options In Connection With The Reverse Merger In Period Intrinsic Value1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumptionOfOptionsInConnectionWithTheReverseMergerInPeriodIntrinsicValue1
177000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
440041
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
12.31
dnth Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value Granted
ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueGranted
159000
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2798
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.66
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
46000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
468291
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
68.14
dnth Share Based Compensation Arrangement By Share Based Payment Award Aggregate Intrinsic Value Forfeited
ShareBasedCompensationArrangementByShareBasedPaymentAwardAggregateIntrinsicValueForfeited
397000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1772179
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
19.04
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
7763000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
699237
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
33.25
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y6M
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
2949000
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
1072942
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
9.78
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
P8Y10M24D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Nonvested
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueNonvested
4814000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
10.86
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.039
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.031
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P6Y
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P5Y10M24D
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.864
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.873
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1179000
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
661000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2174000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1005000
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-14763000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-7784000
us-gaap Net Income Loss
NetIncomeLoss
-32992000
us-gaap Net Income Loss
NetIncomeLoss
-18360000
CY2023Q3 dnth Weightedaveragecommonsharesoutstanding
Weightedaveragecommonsharesoutstanding
3907075
CY2022Q3 dnth Weightedaveragecommonsharesoutstanding
Weightedaveragecommonsharesoutstanding
875279
dnth Weightedaveragecommonsharesoutstanding
Weightedaveragecommonsharesoutstanding
1896983
dnth Weightedaveragecommonsharesoutstanding
Weightedaveragecommonsharesoutstanding
875279
CY2023Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
189
CY2022Q3 us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
952
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
378
us-gaap Weighted Average Number Of Shares Restricted Stock
WeightedAverageNumberOfSharesRestrictedStock
1141
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
3906886
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
3906886
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
874327
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
874327
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1896605
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1896605
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
874138
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
874138
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.78
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.78
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.9
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.9
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-17.4
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-17.4
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-21
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-21
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1987239
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8528101
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1987239
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
8528101

Files In Submission

Name View Source Status
dnth-20230930_cal.xml Edgar Link unprocessable
0000950170-23-062070-index-headers.html Edgar Link pending
0000950170-23-062070-index.html Edgar Link pending
0000950170-23-062070.txt Edgar Link pending
0000950170-23-062070-xbrl.zip Edgar Link pending
dnth-20230930.htm Edgar Link pending
dnth-20230930.xsd Edgar Link pending
dnth-ex10_12.htm Edgar Link pending
dnth-ex31_1.htm Edgar Link pending
dnth-ex31_2.htm Edgar Link pending
dnth-ex32.htm Edgar Link pending
dnth-20230930_def.xml Edgar Link unprocessable
dnth-20230930_lab.xml Edgar Link unprocessable
dnth-20230930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
dnth-20230930_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending